Olivier Sitbon
#123,323
Most Influential Person Now
Researcher
Olivier Sitbon's AcademicInfluence.com Rankings
Olivier Sitboncomputer-science Degrees
Computer Science
#5059
World Rank
#5345
Historical Rank
Machine Learning
#1197
World Rank
#1217
Historical Rank
Artificial Intelligence
#1429
World Rank
#1458
Historical Rank
Olivier Sitbonmathematics Degrees
Mathematics
#5957
World Rank
#8327
Historical Rank
Group Theory
#51
World Rank
#64
Historical Rank
Algebra
#169
World Rank
#258
Historical Rank
Measure Theory
#1042
World Rank
#1341
Historical Rank
Download Badge
Computer Science Mathematics
Olivier Sitbon's Degrees
- PhD Physics Université Paris Cité
Why Is Olivier Sitbon Influential?
(Suggest an Edit or Addition)Olivier Sitbon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pulmonary arterial hypertension in France: results from a national registry. (2006) (1495)
- Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. (2002) (1423)
- Inhaled iloprost for severe pulmonary hypertension. (2002) (1369)
- Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era (2010) (1265)
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study (2001) (1225)
- Pulmonary arterial hypertension (2013) (1158)
- Macitentan and morbidity and mortality in pulmonary arterial hypertension. (2013) (1116)
- Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension (2005) (1078)
- Diagnosis and differential assessment of pulmonary arterial hypertension. (2004) (999)
- Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. (1995) (782)
- Selexipag for the Treatment of Pulmonary Arterial Hypertension. (2014) (641)
- Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. (2002) (636)
- Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension (2010) (614)
- Survival with first-line bosentan in patients with primary pulmonary hypertension (2005) (600)
- Pulmonary Arterial Hypertension in Patients Treated by Dasatinib (2012) (539)
- Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. (2008) (513)
- Updated evidence-based treatment algorithm in pulmonary arterial hypertension. (2009) (512)
- [Treatment of pulmonary arterial hypertension]. (2004) (509)
- Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension (2017) (454)
- Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. (2008) (440)
- Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis (2005) (355)
- Mutations of the TGF‐β type II receptor BMPR2 in pulmonary arterial hypertension (2006) (344)
- EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension (2013) (344)
- Pulmonary hypertension due to left heart disease. (2017) (341)
- Pulmonary vascular disorders in portal hypertension. (1998) (337)
- Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. (2008) (336)
- Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. (2010) (329)
- Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. (2006) (327)
- Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. (2003) (313)
- Pulmonary Veno-Occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology (2008) (306)
- Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. (2008) (303)
- Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. (2006) (301)
- Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. (2003) (300)
- Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study (2014) (299)
- Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. (2011) (299)
- Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. (1998) (282)
- Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. (2010) (275)
- Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. (2006) (275)
- Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension (2014) (261)
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. (2022) (260)
- International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. (2016) (254)
- Severe pulmonary hypertension in histiocytosis X. (2000) (252)
- BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis (2016) (249)
- Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. (1995) (248)
- Severe Pulmonary Hypertension during Pregnancy: Mode of Delivery and Anesthetic Management of 15 Consecutive Cases (2005) (247)
- End points and clinical trial design in pulmonary arterial hypertension. (2004) (246)
- Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. (2004) (245)
- Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. (2004) (243)
- Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension (2009) (229)
- Prostanoid therapy for pulmonary arterial hypertension. (2004) (229)
- Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. (2001) (224)
- Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol (2005) (210)
- Portopulmonary hypertension: survival and prognostic factors. (2008) (210)
- BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives (2002) (206)
- Criteria for diagnosis of exercise pulmonary hypertension (2015) (204)
- Splenectomy and chronic thromboembolic pulmonary hypertension (2005) (200)
- [Treatment goals of pulmonary hypertension]. (2014) (195)
- Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial (2021) (195)
- Chronic thromboembolic pulmonary hypertension (2004) (190)
- Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. (2016) (181)
- Targeted therapies in pulmonary arterial hypertension. (2014) (179)
- HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era (2010) (177)
- [Treatment of pulmonary arterial hypertension]. (2014) (175)
- Long term imatinib treatment in pulmonary arterial hypertension (2006) (173)
- Chronic thromboembolic pulmonary hypertension. (2004) (172)
- ERS statement on chronic thromboembolic pulmonary hypertension (2020) (166)
- EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY (2001) (158)
- Pulmonary veno-occlusive disease (2016) (156)
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆ (2002) (153)
- Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension (1996) (145)
- Treatment of pulmonary arterial hypertension with targeted therapies (2011) (143)
- Chemotherapy-induced pulmonary hypertension: role of alkylating agents. (2015) (142)
- Risk factors for pulmonary arterial hypertension. (2001) (141)
- Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. (2007) (137)
- Occult alveolar haemorrhage in pulmonary veno-occlusive disease (2006) (135)
- Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases (2008) (135)
- Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era (2012) (130)
- French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension (2019) (130)
- Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension (2006) (126)
- Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension (2017) (122)
- Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. (2012) (121)
- Pathways in pulmonary arterial hypertension: the future is here (2012) (114)
- Clinical trial design and new therapies for pulmonary arterial hypertension (2019) (113)
- Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. (1996) (112)
- Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. (2011) (111)
- Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension (2009) (111)
- Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension (2009) (110)
- Initial dual oral combination therapy in pulmonary arterial hypertension (2016) (109)
- Treatment of pulmonary hypertension secondary to connective tissue diseases (1999) (108)
- Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension (2008) (105)
- Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study. (2017) (104)
- Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. (2010) (104)
- Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. (2012) (103)
- Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. (2000) (103)
- Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. (2002) (103)
- Primary pulmonary hypertension associated with the use of fenfluramine derivatives. (1998) (100)
- 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension (2022) (100)
- Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension (2013) (96)
- Minocycline pneumonitis and eosinophilia. A report on eight patients. (1994) (96)
- Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease (2009) (96)
- Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension (2010) (95)
- Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension (2017) (92)
- Treatment goals of pulmonary hypertension. (2013) (92)
- Pulmonary arterial hypertension: thin-section CT predictors of epoprostenol therapy failure. (2002) (87)
- Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension (2017) (87)
- Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension (2012) (87)
- Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation (2020) (86)
- Genetic counselling in a national referral centre for pulmonary hypertension (2015) (85)
- Pulmonary-Hepatic vascular Disorders (PHD) R. Rodriguez-Roisin*, M.J. Krowka # , Ph. Herve ´ } , M.B. Fallon z , on behalf of the ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee (2004) (83)
- Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study (2017) (83)
- Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension (2012) (82)
- Rapid Switch From Intravenous Epoprostenol to Intravenous Treprostinil in Patients With Pulmonary Arterial Hypertension (2007) (82)
- Pulmonary veno-occlusive disease: recent progress and current challenges. (2010) (81)
- Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis (2019) (81)
- Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease (2015) (79)
- Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models. (2015) (78)
- Pulmonary hypertension associated with benfluorex exposure (2012) (78)
- Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. (2019) (78)
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. (2018) (77)
- Endothelin receptor antagonists in pulmonary arterial hypertension. (2004) (76)
- Current and future treatments of pulmonary arterial hypertension (2020) (76)
- Is pulmonary arterial hypertension really a late complication of systemic sclerosis? (2009) (75)
- Fenfluramine-like cardiovascular side-effects of benfluorex (2009) (74)
- Validation of two predictive models for survival in pulmonary arterial hypertension (2015) (73)
- Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study (2017) (73)
- Primary pulmonary hypertension: Current therapy. (2002) (70)
- Pulmonary vascular abnormalities in cirrhosis. (2007) (70)
- Treatment of severe pulmonary hypertension secondary to connective tissue diseases with continuous IV epoprostenol (prostacyclin). (1998) (70)
- Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension (2009) (67)
- Erratum: "Survival with first-line bosentan in patients with primary pulmonary hypertension" (European Respiratory Journal (2005) vol. 25 (244-249)) (2005) (65)
- Pulmonary Hypertension in Patients With Neurofibromatosis Type I (2011) (64)
- Risk assessment in pulmonary arterial hypertension (2018) (64)
- Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis (2002) (63)
- Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study (1999) (63)
- Pulmonary arterial hypertension associated with systemic sclerosis in patients with functional class II dyspnoea: mild symptoms but severe outcome. (2010) (63)
- Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study (2018) (63)
- EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. (2014) (62)
- Pulmonary arterial hypertension in patients treated with interferon (2014) (62)
- BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension (2016) (61)
- Effect of macitentan on hospitalizations: results from the SERAPHIN trial. (2015) (61)
- Prognostic value of exercise pulmonary haemodynamics in pulmonary arterial hypertension (2014) (59)
- Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. (1999) (59)
- Ventilation/perfusion lung scan in pulmonary veno-occlusive disease (2011) (59)
- The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: a practical chronicle of progress (2015) (58)
- Improvement of von Willebrand Factor Proteolysis After Prostacyclin Infusion in Severe Pulmonary Arterial Hypertension (2000) (57)
- Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease (2005) (57)
- Long‐term outcome in liver transplantation candidates with portopulmonary hypertension (2017) (56)
- Portopulmonary hypertension in the current era of pulmonary hypertension management. (2020) (54)
- Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience (2017) (54)
- Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. (2010) (54)
- Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus: Results From the French Pulmonary Hypertension Registry (2018) (53)
- Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study (2015) (53)
- SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension (2017) (53)
- Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects (2006) (51)
- Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension (2018) (50)
- Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals (2010) (50)
- Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats (2010) (50)
- Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. (2012) (49)
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. (2021) (49)
- Chronic thromboembolic pulmonary hypertension. (2015) (48)
- Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. (2016) (47)
- Automatic quantification of right ventricular function with gated blood pool SPECT (2004) (47)
- Lung and heart-lung transplantation for systemic sclerosis patients. A monocentric experience of 13 patients, review of the literature and position paper of a multidisciplinary Working Group. (2014) (46)
- Beyond a single pathway: combination therapy in pulmonary arterial hypertension (2016) (45)
- Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN (2015) (44)
- Macitentan Improves Health‐Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial (2017) (44)
- Hemodynamics in pulmonary arterial hypertension: current and future perspectives. (2012) (44)
- Idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: similarities and differences. (2009) (42)
- HIV-related pulmonary arterial hypertension: clinical presentation and management (2008) (42)
- Systolic and mean pulmonary artery pressures: are they interchangeable in patients with pulmonary hypertension? (2015) (41)
- Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension. (2016) (41)
- Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics (2016) (40)
- Pulmonary veno-occlusive disease: the bête noire of pulmonary hypertension in connective tissue diseases? (2011) (40)
- Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. (2017) (40)
- Association Between Initial Treatment Strategy and Long-term Survival in Pulmonary Arterial Hypertension. (2021) (40)
- Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension (2018) (40)
- Implementing the ESC/ERS pulmonary hypertension guidelines: real-life cases from a national referral centre (2009) (39)
- Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations (2014) (39)
- Pulmonary veno-occlusive disease (2009) (38)
- Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France. (2005) (38)
- Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. (2019) (38)
- Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis (2018) (38)
- Acute decompensated pulmonary hypertension (2017) (38)
- Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission (2021) (37)
- Pulmonary Hypertension Complicating Fibrosing Mediastinitis (2015) (37)
- The Low‐Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal‐oriented Clinical Trial Endpoints? (2017) (37)
- Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity (2016) (37)
- Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: A French multicentre study. (2017) (37)
- EBUS-TBNA in the differential diagnosis of pulmonary artery sarcoma and thromboembolism (2012) (35)
- Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution (2009) (35)
- Review: Therapeutic advances in pulmonary arterial hypertension (2008) (35)
- [Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis]. (2010) (34)
- Inspiratory muscle function, dynamic hyperinflation and exertional dyspnoea in pulmonary arterial hypertension (2015) (34)
- RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study (2018) (34)
- Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of bone morphogenetic protein receptor type 2. (2015) (32)
- Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension (2016) (32)
- Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension (2019) (31)
- Gut-Lung Connection in Pulmonary Arterial Hypertension. (2017) (31)
- Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study (2019) (31)
- Interferon-induced pulmonary hypertension: an update (2016) (30)
- Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry. (2014) (30)
- Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial (2018) (30)
- Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension (2015) (29)
- Dead-space ventilation is linked to exercise capacity and survival in distal chronic thromboembolic pulmonary hypertension. (2017) (28)
- Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension (2020) (28)
- Clinical challenges in pulmonary hypertension: Roger S. Mitchell lecture. (2005) (28)
- Diagnostic concordance of different criteria for exercise pulmonary hypertension in subjects with normal resting pulmonary artery pressure (2016) (27)
- Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension (2002) (27)
- New pharmacotherapy options for pulmonary arterial hypertension (2015) (27)
- [Guidelines for the diagnosis and treatment of pulmonary hypertension]. (2010) (26)
- Left ventricular ejection time in acute heart failure complicating precapillary pulmonary hypertension. (2013) (26)
- Effect of Macitentan on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the SERAPHIN Trial (2012) (26)
- External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry (2021) (25)
- The association between resting and mild-to-moderate exercise pulmonary artery pressure (2011) (25)
- Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. (2022) (25)
- Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study (2018) (25)
- Current management approaches to portopulmonary hypertension (2011) (25)
- Pulmonary arterial hypertension and HIV infection. (2009) (25)
- Pharmacokinetic evaluation of sildenafil as a pulmonary hypertension treatment (2013) (25)
- Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation (2020) (24)
- Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial (2021) (24)
- Optimal management of severe pulmonary arterial hypertension (2011) (23)
- Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. (2017) (23)
- Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study (2020) (23)
- Factors predicting outcome after pulmonary endarterectomy (2018) (23)
- Exertional dyspnoea in pulmonary arterial hypertension (2017) (22)
- Pulmonary hypertension associated with neurofibromatosis type 1 (2018) (22)
- Late Breaking Abstract - Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension: results from the randomised controlled RACE study (2019) (22)
- Pulmonary arterial hypertension in idiopathic inflammatory myopathies (2016) (22)
- Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension (2019) (22)
- Portopulmonary Hypertension (2017) (22)
- A Clinical and Echocardiographic Score to Identify Pulmonary Hypertension Due to HFpEF. (2017) (21)
- Mitomycin-Induced Pulmonary Veno-Occlusive DiseaseCLINICAL PERSPECTIVE (2015) (21)
- Out-of-Proportion Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (2012) (21)
- Long-term outcomes of pulmonary arterial hypertension under specific drug therapy in Eisenmenger syndrome. (2017) (21)
- Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension. (2014) (20)
- Fatal dissection of the pulmonary artery in pulmonary arterial hypertension (2009) (20)
- French recommendations for the management of systemic sclerosis (2021) (19)
- Serum and pulmonary uric acid in pulmonary arterial hypertension (2021) (19)
- Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension with Oral Prostacyclin Pathway Agents. (2019) (19)
- [Pulmonary artery hypertension associated with connective tissue diseases]. (2003) (19)
- Validation of a risk assessment instrument for pulmonary arterial hypertension (2018) (18)
- Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors (2020) (18)
- Impact of the initiation of balloon pulmonary angioplasty program on referral of patients with chronic thromboembolic pulmonary hypertension to surgery. (2018) (18)
- A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension (2015) (18)
- Calcium-channel blockers in pulmonary arterial hypertension. (2013) (18)
- The study of risk in pulmonary arterial hypertension (2012) (18)
- Hypertension pulmonaire postembolique (2007) (18)
- Pulmonary arterial hypertension in patients treated with interferon (2014) (18)
- Novel therapeutic perspectives in pulmonary arterial hypertension (2003) (17)
- Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease (2018) (17)
- Patients', relatives', and practitioners' views of pulmonary arterial hypertension: A qualitative study. (2016) (17)
- Phenotype and outcome of pulmonary arterial hypertension patients carrying a TBX4 mutation (2020) (16)
- Idiopathic pulmonary hypertension: what did we learn from genes? (2005) (16)
- Association of NT-proBNP and Long-Term Outcome in Patients with Pulmonary Arterial Hypertension: Insights from the Phase III GRIPHON Study (2019) (16)
- Risk stratification in pulmonary arterial hypertension (2018) (15)
- Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease. (2019) (15)
- Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease (2019) (15)
- Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence (2005) (14)
- Pharmacokinetic evaluation of continuous intravenous epoprostenol (2010) (14)
- Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. (2021) (14)
- Inflammatory Mechanisms in HIV-Associated Pulmonary Arterial Hypertension (2013) (14)
- [Porto-pulmonary hypertension]. (2006) (14)
- Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. (2017) (13)
- Pulmonary venoocclusive disease and failure of specific therapy. (2009) (13)
- The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study (2021) (13)
- [Pulmonary arterial hypertension of chronic thrombo-embolic origin. 70 patients]. (1994) (13)
- Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. (2010) (13)
- TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension (2021) (13)
- Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution (2020) (13)
- Hypertension artérielle pulmonaire postembolique tumorale (2007) (13)
- Renal Replacement Therapy in Patients with Severe Precapillary Pulmonary Hypertension with Acute Right Heart Failure (2012) (13)
- Direct-Acting Antiviral Medications for Hepatitis C Virus Infection and Pulmonary Arterial Hypertension. (2016) (13)
- Non-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension (2015) (12)
- Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry (2018) (12)
- Treatment of pulmonary arterial hypertension. (2004) (12)
- Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension (2011) (12)
- Riociguat: Clinical research and evolving role in therapy (2020) (12)
- [Biomarkers as prognostic factors in pulmonary arterial hypertension. Rationale and study design]. (2004) (11)
- Natural History over 8 Years of Pulmonary Vascular Disease in a Patient Carrying Biallelic EIF2AK4 Mutations. (2018) (11)
- Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension. (2022) (11)
- Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis (2020) (11)
- Age, risk and outcomes in idiopathic pulmonary arterial hypertension (2018) (10)
- Sex and gender in pulmonary arterial hypertension (2021) (10)
- Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs (2021) (10)
- [Pulmonary arterial hypertension due to tumor emboli]. (2007) (10)
- Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris Tracking Study. (2017) (10)
- Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee (2016) (10)
- BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT) (10)
- Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database (2019) (10)
- Upfront Triple Combination Therapy Of I.V. Epoprostenol With Oral Bosentan And Sildenafil In Idiopathic And Heritable Pulmonary Arterial Hypertension (2011) (9)
- Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome (2021) (9)
- Biomarkers for the prognosis of pulmonary arterial hypertension: Holy Grail or flying circus? (2014) (9)
- Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension (2018) (9)
- [Treatments for pulmonary arterial hypertension]. (2004) (9)
- Intramuscular triamcinolone in severe asthma. (1991) (9)
- Characteristics and long-term outcomes of pulmonary veno-occlusive disease induced by Mitomycin-C. (2020) (9)
- Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. (2021) (9)
- Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension (2019) (9)
- [Pulmonary hypertension in liver diseases]. (2014) (8)
- [Pulmonary hypertension and obesity]. (2002) (8)
- Management of pulmonary arterial hypertension in patients aged over 65 years (2019) (8)
- Lung capillary blood volume and membrane diffusion in precapillary pulmonary hypertension. (2016) (8)
- Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France (2020) (8)
- COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study (2022) (8)
- Computed Tomography Findings Of Pulmonary Veno-Occlusive Disease In Scleroderma Patients Presenting With Precapillary Pulmonary Hypertension (2012) (8)
- Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH) (2013) (7)
- Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension. (2015) (7)
- Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension (2021) (7)
- Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems (2020) (7)
- External validation of the REVEAL risk score calculator for PAH survival: A French pulmonary hypertension network analysis (2012) (7)
- [Genetics of pulmonary arterial hypertension: recent data and practical applications]. (2005) (7)
- [Clinical, haemodynamic and genetic features of familial pulmonary arterial hypertension]. (2004) (7)
- Pulmonary arterial hypertension in familial hemiplegic migraine with ATP1A2 channelopathy (2013) (7)
- Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH) (2014) (7)
- Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases. (2020) (7)
- Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. (2020) (7)
- Kinetics of Cardiac Output at the Onset of Exercise in Precapillary Pulmonary Hypertension (2016) (7)
- Medical Treatment of Pulmonary Arterial Hypertension (2017) (7)
- Chronic Thromboembolic Pulmonary Hypertension Associated With Indwelling Port-A-Cath® Central Venous Access Systems (2011) (7)
- Phenotype and outcome of PAH patients carrying a TBX4 mutation. (2020) (7)
- PH CARE COVID survey: an international patient survey on the care for pulmonary hypertension patients during the early phase of the COVID-19 pandemic (2021) (7)
- Hemoptysis in Pulmonary Arterial Hypertension (PAH): A Life-Threatening Complication. (2009) (7)
- The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension (2014) (7)
- [Treatment for pulmonary arterial hypertension under the new French hospital financing system. Recommendations of the Pulmonary Vascular Diseases Working Group of the French Society of Pulmonary Medicine]. (2005) (7)
- [Tunnelled central venous line-associated infections in patients with pulmonary arterial hypertension treated with intravenous prostacyclin]. (2016) (6)
- Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension (2020) (6)
- Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases (2019) (6)
- Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension (2004) (6)
- Response to Letter Regarding Article, "Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Model". (2016) (6)
- Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. (2022) (6)
- Mediastinal fibrosis mimicking proximal chronic thromboembolic disease. (2012) (6)
- Pulmonary arterial hypertension (2004) (6)
- Successful treatment of disseminated cryptococcosis with high-dose oral fluconazole. (1993) (6)
- Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial (2018) (6)
- Cirrhosis ameliorates monocrotaline-induced pulmonary hypertension in rats (2009) (6)
- [Pulmonary arterial hypertension of chronic thromboembolic origin; therapeutic indications]. (1994) (6)
- Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (2018) (6)
- The changing picture of patients with pulmonary arterial hypertension (PAH) in France (2011) (6)
- [Pulmonary arterial hypertension associated with common diseases: connective-tissue diseases, HIV infection and portal hypertension]. (2008) (6)
- Impact of Initial Triple Combination Therapy on Long-Term Survival in Pulmonary Arterial Hypertension (PAH) (2019) (5)
- Assessing effectiveness of pulmonary arterial hypertension therapies in daily practice (2010) (5)
- A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica (2016) (5)
- Catheter Related-infections In Pulmonary Hypertension Patients Treated By Continuous Intravenous Epoprostenol: Experience Of The French Referral Centre (2010) (5)
- Association between Leflunomide and Pulmonary Hypertension. (2021) (5)
- Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure. (2011) (5)
- Pulmonary arterial hypertension registries: past, present and into the future (2019) (5)
- Impact Of Pulmonary Arterial Hypertension Specific Therapy On Portopulmonary Hypertension (2010) (5)
- An emerging phenotype of pulmonary arterial hypertension patients carrying SOX17 variants (2022) (5)
- Survival improved in systemic sclerosis associated pulmonary arterial hypertension patients aged 70 years or less over the period 2006-2017 in France. (2019) (5)
- Hypertension artérielle pulmonaire primitive (2002) (5)
- EPITOME-2, An Open-Label Study Evaluating A New Formulation Of Epoprostenol Sodium In Pulmonary Arterial Hypertension Patients Switched From Flolan® (2012) (5)
- The isobaric pulmonary arterial compliance in pulmonary hypertension (2021) (5)
- Pulmonary arterial hypertension: combination therapy in the modern management era (2010) (5)
- 829 Care Organisation for Pulmonary Arterial Hypertension in Developed Countries: A Survey (2012) (4)
- Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy (2013) (4)
- Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension (2018) (4)
- Effects Of HIV Protease Inhibitors On Progression Of Monocrotaline-induced Pulmonary Hypertension In Rats (2010) (4)
- Nasal decongestant exposure in patients with pulmonary arterial hypertension: a pilot study (2015) (4)
- External validation of the French predictive model to estimate PAH survival: A REVEAL analysis (2012) (4)
- Impact of macitentan on the health-related quality of life (HRQoL) in pulmonary arterial hypertension (PAH): Results from a long-term randomised controlled trial (2013) (4)
- Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment (2014) (4)
- Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities (2019) (4)
- Response to Letter Regarding Article, "Advances in Therapeutic Interventions for Patients With Pulmonary Arterial Hypertension". (2015) (4)
- Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence (2009) (4)
- Center-based Care for Pulmonary Hypertension: A European Perspective (2018) (4)
- Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver. (2020) (4)
- A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study (2019) (4)
- [Pulmonary hypertension associated with systemic sclerosis]. (2002) (4)
- Hypoxemia during sleep and overnight rostral fluid shift in pulmonary arterial hypertension: a pilot study (2021) (4)
- Pulmonary Hypertension in Patients with Common Variable Immunodeficiency (2021) (4)
- [Chronic pulmonary thromboembolism revealing beta-thalassemia intermedia after splenectomy]. (2006) (4)
- Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension. (2019) (4)
- Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure (2021) (4)
- SERIES "ADVANCES IN PATHOBIOLOGY, DIAGNOSIS, AND TREATMENT OF PULMONARY HYPERTENSION" Edited by A.T. Dinh-Xuan, M. Humbert, R. Naeije Number 10 in this Series Chronic thromboembolic pulmonary hypertension (2004) (3)
- Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal: a proof of concept study (2017) (3)
- Using controlled and real-world data in concert to assess survival benefits in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL (2017) (3)
- Portopulmonary hypertension: light at the end of the tunnel? (2012) (3)
- Are indexed values better for defining exercise pulmonary hypertension? (2017) (3)
- Pulmonary Arterial Hypertension and HIV and Other Viral Infections (2012) (3)
- Relation between left ventricular ejection time and pulmonary hemodynamics in pulmonary hypertension. (2015) (3)
- Late Breaking Abstract - Screening of pulmonary arterial hypertension in asymptomatic BMPR2 mutation carriers (DELPHI-2 Study) (2019) (3)
- FRI0245 Survival and prognostic factors in patients with incident systemic sclerosis-associated pulmonary arterial hypertension from the french registry (2011) (3)
- Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension (2020) (3)
- Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) (2018) (3)
- Reduction Of Pulmonary Arterial Hypertension (Pah)-Related Hospitalizations With Macitentan In The Randomized Controlled Trial Seraphin (2013) (3)
- Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan (2013) (3)
- Pulmonary Hypertension In Patients Treated By Dasatinib (2012) (3)
- Bosentan therapy for pulmonary arterial hypertension. (2005) (3)
- The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH) (2019) (3)
- Circulating Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension and Cirrhotic Portopulmonary Hypertension. (2009) (3)
- Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. (2022) (3)
- Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH) (2015) (3)
- Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. (2022) (3)
- EPITOME-2: Evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulation (2012) (2)
- [Pulmonary veno-occlusive disease]. (2018) (2)
- Effect of macitentan on haemodynamics in patients with pulmonary arterial hypertension: results from the long-term, randomised, placebo-controlled SERAPHIN trial (2013) (2)
- Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. (2020) (2)
- mutation type on clinical phenotypes of pulmonary arterial hypertension (2010) (2)
- Management of selexipag interruptions in the GRIPHON study (2016) (2)
- Pulmonary hypertension related to appetite suppressants (2011) (2)
- [Treatment goals in pulmonary arterial hypertension]. (2010) (2)
- 2568 Haemodynamic and clinical improvement with bosentan in patients with pulmonary arterial hypertension associated with HIV infection (2003) (2)
- Outcome of Heart-Lung or Double-Lung Transplantation in Pulmonary Hypertension Secondary to Congenital Heart Diseases (2018) (2)
- Pulmonary arterial hypertension: genetics, reversibility testing and follow-up. (2004) (2)
- Risk categories from European guidelines applied to the French Pulmonary Hypertension (PH) registry (2017) (2)
- CONTINUOUS SUBCUTANEOUS INFUSION OF REMODULIN, A PROSTACYCLIN ANALOGUE, IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: LONG-TERM OUTCOME (ABSTRACT 1203) (2001) (2)
- Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results (2015) (2)
- Comparing cardiac magnetic resonance imaging in group 1 and group 4 pulmonary hypertension (2011) (2)
- [HIV-related pulmonary arterial hypertension]. (2012) (2)
- Anticoagulant Therapy Is Not Associated with Long Term Outcome in Patients with Pulmonary Arterial Hypertension (PAH): Insights from the GRIPHON Study (2016) (2)
- [Surgical treatment of chronic thromboembolic pulmonary hypertension]. (2005) (2)
- Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study (2020) (2)
- New trends in pulmonary hypertension (2023) (2)
- Effects of 12-week exercise training-related rehabilitation on exertional dyspnoea in patients with idiopathic pulmonary arterial hypertension (2015) (2)
- Traitement chirurgical de l’hypertension artérielle pulmonaire post-embolique (2004) (2)
- A New Definition Of Exercise Induced Pulmonary Hypertension (2012) (2)
- Early selexipag initiation and long-term outcomes: Insights from RCTs in PAH (2022) (2)
- Current pulmonary hypertension guidelines and remaining controversies (2010) (2)
- [Management of right ventricular failure in pulmonary vascular diseases]. (2020) (2)
- Addition of Sildenafil to First Line Bosentan Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension. (2009) (2)
- Efficacy and safety of tadalafil in portopulmonary hypertension (2018) (2)
- Pulmonary hypertension associated with busulfan (2021) (2)
- Lung Ventilation/Perfusion Scintigraphy for the Screening of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Which Criteria to Use? (2022) (2)
- The dangerous and contradictory prognostic significance of PVR<3WU when TAPSE<16mm in postcapillary pulmonary hypertension (2020) (2)
- INITIAL TREATMENT COMBINATION WITH MACITENTAN AND TADALAFIL IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM THE OPTIMA STUDY (2019) (2)
- Validation Of The French Pulmonary Hypertension Network Equation To Estimate Survival: A REVEAL Analysis (2012) (2)
- Clinical Outcomes of PAH Patients Walking More Than 450m in 6-Min at the Time of Diagnosis. (2009) (2)
- Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis (2021) (2)
- Treat-to-target approach in pulmonary arterial hypertension: a consensus-based proposal (2012) (2)
- Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success? (2011) (2)
- Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension (2018) (2)
- Pulmonary Hypertension Complicating Pulmonary Artery Involvement in Pseudoxanthoma Elasticum. (2020) (2)
- Acute Vasodilator Testing in PAH (2003) (1)
- Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers (2021) (1)
- Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading (2018) (1)
- Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension (2013) (1)
- ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly (2022) (1)
- Pulmonary Vascular Resistance in Pulmonary Arterial Hypertension: La Pièce de Résistance? (2020) (1)
- Highlights from the ERS International Congress 2018: Assembly 13 – Pulmonary Vascular Diseases (2019) (1)
- The Angle Between The Interventricular Septum And The Left Ventricular Free Wall As A New Index Of Right Ventricular Overload In Pulmonary Hypertension Patients: A Cardiac Magnetic Resonance Study (2011) (1)
- Initial combination of macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension (PAH): results from the OPTIMA study (2017) (1)
- S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (pah): insights from the randomised controlled griphon trial with selexipag (2016) (1)
- Characteristics Of Severe Pulmonary Hypertension Associated With COPD In A French Multicenter Study (2016) (1)
- Cytokines as prognostic biomarkers in pulmonary arterial hypertension (2022) (1)
- Auranofin in steroid dependent asthma. (1992) (1)
- [Postembolic pulmonary hypertension]. (2007) (1)
- Survival in portopulmonary hypertension (PoPH) in the era of modern PAH-targeted therapy (2018) (1)
- 108 Endothelin-1 and Endothelin-3 plasma levels in severe pulmonary arterial hypertension (2005) (1)
- Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri®): a prospective, 6-months, open label, observational, non-interventional study (2023) (1)
- Five-years experience with high urgency allocation program for lung and heart-lung transplantation in pulmonary hypertension (2014) (1)
- Accuracy of transpulmonary thermodilution cardiac output measurement (PiCCO) in patients with right heart failure (RHF) due to precapillary pulmonary hypertension (PH) (2013) (1)
- Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations (2020) (1)
- World Health Organization classification and risk factors for pulmonary arterial hypertension (2004) (1)
- 3016Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (2018) (1)
- SELEXIPAG FOR PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE (PAH-CHD) AFTER DEFECT CORRECTION: INSIGHTS FROM THE RANDOMISED CONTROLLED GRIPHON STUDY (2016) (1)
- [Liver diseases and pulmonary vascular disorders]. (2018) (1)
- Assembly 13: placing the pulmonary circulation in the heart of ERS (2019) (1)
- Outcome of candidates for liver transplantation suffering from portopulmonary hypertension (2013) (1)
- , Hypertension Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial (2005) (1)
- [Pulmonary hypertension associated with connective tissue diseases]. (2002) (1)
- Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. (2021) (1)
- Chemosensitivity and ventilatory inefficiency in pulmonary vascular diseases (2017) (1)
- Idiopathic pulmonary arterial hypertension in the elderly: Data from the French registry (2011) (1)
- HIV-Associated Pulmonary Arterial Hypertension: Survival and Prognostic Factors in the Current Therapeutic Era. (2009) (1)
- Gas Exchange and Ventilatory Efficiency During Exercise in Pulmonary Vascular Diseases (2020) (1)
- Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension? (2021) (1)
- Portopulmonary Hypertension and Hepatopulmonary Syndrome (2012) (1)
- Late Breaking Abstract - COVID-19 in patients with pulmonary hypertension: a national prospective cohort study (2021) (1)
- Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension (2021) (1)
- Algorithm for pulmonary hypertension screening in sarcoidosis: A Delphi Consensus (2019) (1)
- Six-Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension (2015) (1)
- EFFECT OF MACITENTAN ON HEMODYNAMICS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: Results FROM THE LONG-TERM, RANDOMISED, PLACEBO-CONTROLLED SERAPHIN TRIAL (2014) (1)
- Corrigendum to: "Portopulmonary hypertension in the current era of pulmonary hypertension management" [J Hepatol (2020);73:130-139]. (2020) (1)
- Correcting For Age And Sex Unmasks Decreased Right Ventricular Ejection Fraction In Pulmonary Hypertension (2011) (1)
- Prognostic value of respiratory variables in candidates for liver transplantation (2021) (1)
- FRI0299 Pulmonary Arterial Hypertension in Idiopathic Inflammatory Myopathies: Data from The French Pulmonary Hypertension Registry and Review of The Literature (2016) (1)
- OP0094 PULMONARY ARTERIAL HYPERTENSION IN ADULT-ONSET STILL’S DISEASE: A CASE SERIES OF 13 PATIENTS (2021) (1)
- European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology (2023) (1)
- Is there an obesity paradox in pulmonary arterial hypertension (2017) (1)
- Predictors of Outcome in Patients with Pulmonary Arterial Hypertension with Right Ventricular Failure Requiring Intensive Care Admission. (2009) (1)
- Basic (PS01–PS58) (2012) (1)
- Severe Pulmonary Hypertension Management Across Europe (PHAROS): an ERS Clinical Research Collaboration (2020) (1)
- Chronic thromboembolic pulmonary hypertension associated with Klippel Trenaunay syndrome: A retrospective series of 5 patients (2011) (1)
- Contribution of increased afterload to right ventricular ejection fraction in pulmonary hypertension (2011) (1)
- Outcome of Portopulmonary Hypertension After Liver Transplantation: Perhaps Not So Optimistic. (2018) (1)
- Impact Of Exercise Pulmonary Hemodynamic In Idiopathic, Heritable And Anorexigen-Associated Pulmonary Arterial Hypertension (2012) (1)
- Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units (2022) (1)
- [A case of severe colitis with positive hemocultures for Shigella flexneri]. (1987) (1)
- [Lung transplantation for severe pulmonary hypertension]. (2023) (0)
- Small airways dysfunction in chronic thromboembolic pulmonary hypertension (2015) (0)
- [Acute lipid pneumopathy]. (1995) (0)
- [Updated indications and contraindications in 2022 for lung transplantation in France]. (2022) (0)
- 4d cardiac magnetic resonance flow in patients with pulmonary arterial hypertension associated with congenital heart disease (2020) (0)
- Detection of Antibodies to Tenascin-C in Patients with Idiopathic Pulmonary Arterial Hypertension. (2009) (0)
- Autoévaluations de l'article : Complications pulmonaires de l'hypertension portale (2014) (0)
- Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension. (2023) (0)
- [2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. (2023) (0)
- [Native renal hydatidosis. A rare cause of prolonged fever]. (1990) (0)
- Reply to Jha (2022) (0)
- Incidental finding of elevated pulmonary arterial pressures during liver transplantation and postoperative pulmonary complications (2022) (0)
- Faculty Opinions recommendation of Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. (2006) (0)
- Prostanoid Treatment for Pulmonary Arterial Hypertension (2008) (0)
- Images in Cardiovascular Medicine Mediastinal Fibrosis Mimicking Proximal Chronic Thromboembolic Disease (2012) (0)
- Sildenafil citrate therapy for pulmonary arterial hypertension (vol 353, pg 2148, 2005) (2006) (0)
- [Risk factors in venous thromboembolism]. (1998) (0)
- [Therapeutic management of porto-pulmonary hypertension. Complication of portal hypertension: how to treat pleuro-pulmonary complications?]. (2004) (0)
- Prognostic value of hemodynamics following treatment initiation in pulmonary arterial hypertension (2017) (0)
- Abstracts, Oral communications, Tuesday, 3 September 2002 (2002) (0)
- Equilibrium ECG-gated Tc-99m SPECT radionuclide angiography (RNA) in chronic thromboembolic pulmonary hypertension (CTE-PH) (1999) (0)
- Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice (2015) (0)
- Reply to Jin et al. and to Sun et al. (2021) (0)
- Genetic Counselling In The French Pulmonary Hypertension Referral Center (2012) (0)
- Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension (2023) (0)
- Predictors of a precapillary component in patients with postcapillary pulmonary hypertension (2020) (0)
- Ralinepag, an Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis (2018) (0)
- 11 Echocardiography as reproducible and relevant tool in PAH? Intermediate results of the multicentric EFORT echocardiographic substudy (Evaluation of prognostic factors and therapeutic targets in PAH) (2015) (0)
- Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension (2021) (0)
- Hemodynamic correlates of right ventricular dilation in pulmonary hypertension due to HFpEF (2018) (0)
- ResearchAbsence of influence of gender and BMPR 2 mutation type on clinical phenotypes of pulmonary arterial hypertension (2010) (0)
- PRS12 - DEVELOPMENT AND VALIDATION OF AN ALGORITHM IDENTIFYING CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) IN HOSPITAL DISCHARGE DATABASES (2018) (0)
- In-depth characterization of pulmonary arterial hypertension in mixed connective tissue disease: a French national multicenter study. (2023) (0)
- P2614Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era (2018) (0)
- Clinical phenotypes and outcomes of severe pulmonary hypertension associated with chronic obstructive pulmonary disease (2022) (0)
- 16.52 Validation of an “echocardiography-like” method for right- ventricular function evaluation applied to ECG-gated blood pool tomography (2001) (0)
- Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib (2011) (0)
- Inspiratory muscle constraint during exercise in patients with pulmonary arterial hypertension (2012) (0)
- Identifying chronic thromboembolic pulmonary hypertension (CTEPH) through French national hospital database (PMSI) (2018) (0)
- 16.47 Right and left ventricular interaction in chronic post-embolic pulmonary hypertension: a model for predicting the limits of normal left ventricular ejection fraction (2001) (0)
- Autochthonous renal hydatidosis. A rare cause of prolonged fever. (1990) (0)
- Epoprostenol Therapy as a Life Saving Bridge to Lung Transplantation for Pulmonary Veno-Occlusive Disease. (2009) (0)
- Initial dual oral combination therapy prior to pulmonary endarterectomy (PEA) in patients with operable chronic thromboembolic pulmonary hypertension (CTEPH) and high preoperative pulmonary vascular resistance (PVR) (2020) (0)
- Echographic characteristics of PH in HFpEF and precapillary PH (2017) (0)
- Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension (2022) (0)
- ndothelin Receptor Antagonists n Pulmonary Arterial Hypertension (2016) (0)
- [Patient suddenly breathless]. (2018) (0)
- with common bile duct ligation Hypoxic pulmonary hypertension is prevented in rats (2015) (0)
- [Evaluation of cardiac MRI in the follow up assessment of patients with pulmonary arterial hypertension]. (2018) (0)
- OP0096 Relevance of the 6-Minute Walking Test in Assessing the Severity of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Interstitial Lung Disease (2014) (0)
- SPRING SEAT AND BEARING CONNECTION IN A SUSPENSION STRUT (1999) (0)
- Reduced exercise capacity in a mouse model of asthma (2006) (0)
- Pulmonary arterial hypertension in idiopathic in fl ammatory myopathies Data from the French pulmonary hypertension registry and review of the literature (2016) (0)
- Reply to: "Management of portopulmonary hypertension: What is more important, PAH severity or liver disease severity?" (2020) (0)
- For a better estimation of pulmonary pressures by echocardiography: Need for quality improvement (2020) (0)
- Initial Triple Oral Therapy in Pulmonary Arterial Hypertension (PAH): Extended Long-Term Outcome Data from TRITON (2021) (0)
- Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the French PAH registry (2011) (0)
- Reversible pulmonary hypertension associated with multivisceral Whipple's disease (2020) (0)
- Clinical features of pulmonary hypertension (2011) (0)
- MACITENTAN TREATMENT EFFECT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION TAKING SPIRONOLACTONE: POST-HOC ANALYSIS OF THE PHASE 3 SERAPHIN TRIAL (2021) (0)
- Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: A retrospective, observational cohort study in France. (2022) (0)
- Modeling survival using decision tree analysis in pulmonary hypertension due to left heart disease. the prognostic significance of PVR <3WU when TAPSE <16mm (2020) (0)
- during experimental chronic pulmonary hypertension Combined inhaled nitric oxide and inhaled prostacyclin (2015) (0)
- Bacterial translocation in pulmonary hypertension (2017) (0)
- Prognostic value of renal doppler in acute decompensated precapillary pulmonary hypertension (2021) (0)
- PS-008 Exposure to vasoconstrictor nasal decongestants in patients with pulmonary arterial hypertension (2014) (0)
- Severe pediatric pulmonary arterial hypertension: Long-term outcomes of reverse Potts shunt and transplantation (2022) (0)
- Clinical phenotypes and outcomes of pulmonary veno-occlusive disease in carriers of bi-allelicEIF2AK4mutations (2016) (0)
- Joint Annual Meeting of the Swiss Society for Allergology and Immunology and the Swiss Respiratory Society, Bern, April 17-19, 2013 (2013) (0)
- Long-term outcome of sarcoidosis-associated pulmonary hypertension in the modern treatment era (2015) (0)
- REVEAL LITE 2 RISK ASSESSMENT IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION FROM THE GRIPHON STUDY: A POST-HOC ANALYSIS DEMONSTRATES ASSOCIATION OF RISK STATUS WITH LONG-TERM OUTCOMES (2021) (0)
- [Treatment of pulmonary arterial hypertension in 2011: what's new since the 2009 ERS/ESC guidelines?]. (2011) (0)
- Long-Term Safety and Tolerability of a New Formulation of Epoprostenol in Pulmonary Arterial Hypertension (PAH) Patients: Final Results from EPITOME-2 (2016) (0)
- Genetic counselling in pulmonary arterial hypertension: Experience from the French referal centre (2011) (0)
- Characteristics and management of chronic thromboembolic pulmonary disease patients without pulmonary hypertension in an expert centre (2022) (0)
- Anesthesia for Patients with Pulmonary Arterial Hypertension Undergoing Non-Cardiac, Non-Obstetric Surgery. (2009) (0)
- Frequency and impact on prognosis of signs of pulmonary veno-occlusive disease on high resolution computed tomography in patients with scleroderma associated pulmonary arterial hypertension (2011) (0)
- Risk stratification in patients with pulmonary arterial hypertension (PAH) and candidates for lung or heart-lung transplantation (2021) (0)
- Reply to: Effect of Covid-19 Infection in Pulmonary Hypertension. (2022) (0)
- Do respiratory mechanics abnormalities contribute to exertional dyspnoea in patients with pulmonary hypertension (2011) (0)
- Balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (2018) (0)
- 16.46 Impact of the etiology of pulmonary hypertension on right ventricular function: primary pulmonary hypertension versus chronic post-embolic pulmonary hypertension (2001) (0)
- Predictors of A Pre-Capillary Component in Patients with Post-Capillary Pulmonary Hypertension (2020) (0)
- Noninvasive prediction of pre-capillary pulmonary hypertension (PH) component in patients with post-capillary PH (2023) (0)
- Prognostic value of hemodynamic parameters in pulmonary arterial hypertension associated to congenital heart diseases (2022) (0)
- [Diagnosis and classification of pulmonary arterial hypertension]. (2005) (0)
- [Pulmonary artery hypertension: therapeutic progress]. (2003) (0)
- Pulmonary hypertension associated with neurofibromatosis type 1: data from the French Pulmonary Hypertension Registry (2019) (0)
- Characteristics and outcomes of heritable pulmonary veno-occlusive disease due toEIF2AK4mutations (2015) (0)
- Screening of pulmonary arterial hypertension in BMPR2 mutation carriers (2020) (0)
- PROSTACYCLIN INTERNATIONAL EXPERT PANEL CONSENSUS-BASED RECOMMENDATIONS FOR THE USE OF SELEXIPAG IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (2019) (0)
- 262. Physiology of human pulmonary hypertension (2011) (0)
- Non-invasive diagnosis of pulmonary hypertension from lung Doppler signal (2015) (0)
- Iconographies supplémentaires de l'article : Complications pulmonaires de l'hypertension portale (2014) (0)
- Factors associated with survival in patients with not-operated chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era (2018) (0)
- Current epoprostenol use in patients with severe pulmonary hypertension (PH): Data from the French PH registry (2011) (0)
- 330 Characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease in the registry of the French PAH network (2012) (0)
- S94 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON (2021) (0)
- Right heart failure (2016) (0)
- Iconography : Chronic thromboembolic pulmonary hypertension (2015) (0)
- Iconography : Hypertension artérielle pulmonaire (2009) (0)
- 0425: Prognostic value of invasive hemodynamic parameters in Eisenmenger syndrome (2015) (0)
- Exercise capacity : from elite athletes to severe impairment P 839 Factors predicting exercise-induced oxygen desaturation in stable COPD (2012) (0)
- Multiparametric evaluation of right ventricular function in pulmonary arterial hypertension associated with congenital heart disease. (2022) (0)
- The Registry Data Warehouse in the European Reference Network for Rare Respiratory Diseases - Background, Conception and Implementation (2021) (0)
- Sequential multimodal therapy in patients with chronic thromboembolic pulmonary hypertension (CTEPH) (2020) (0)
- Initial triple therapy in pulmonary arterial hypertension: coming of age and rejuvenated (2021) (0)
- Pulmonary hypertension associated with portal hypertension (2011) (0)
- 16.48 Can ECG-gated blood pool tomography be used for the evaluation of the severity and in the follow-up of patients with chronic post-embolic pulmonary hypertension (2001) (0)
- Arbres décisionnels de l'article : Complications pulmonaires de l'hypertension portale (2014) (0)
- Genetic determinants of risk and survival in pulmonary arterial hypertension (2018) (0)
- Short title: Bosentan in portopulmonary hypertension (2012) (0)
- SAFETY AND EFFICACY OF MACITENTAN IN ELDERLY PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM SERAPHIN (2020) (0)
- Pulmonary arterial hypertension associated with HIV infection (2018) (0)
- Pulmonary arterial hypertension-related morbidity is prognostic for survival: Insights from the SERAPHIN and GRIPHON studies (2017) (0)
- 4D cardiac magnetic resonance flow in patients with pulmonary hypertension associated with congenital heart disease (2019) (0)
- Mitomycin-induced pulmonary veno-occlusive disease: Experience from the French pulmonary hypertension network (2015) (0)
- 2022 Update of indications and contraindications for lung transplantation in France. (2022) (0)
- Morphology and rheology of pulmonary arteries: A relationship with right ventricular function in patients with pulmonary arterial hypertension associated with atrial septal defect? (2022) (0)
- SERIES ''PULMONARY HYPERTENSION: BASIC CONCEPTS FOR PRACTICAL MANAGEMENT'' Edited by M.M. Hoeper and A.T. Dinh-Xuan Number 7 in this Series Pulmonary veno-occlusive disease (2009) (0)
- Association between Leflunomide and Pulmonary Hypertension (2021) (0)
- Characteristics and outcome of patients with pre-capillary pulmonary hypertension who were drained for tamponade: A monocentric study (2013) (0)
- Pulmonary hypertension: its assessment and treatment (1999) (0)
- Portopulmonary hypertension: An unfolding story. (2020) (0)
- Pulmoner hipertansiyonda tedavi hedefleri Treatment goals of pulmonary hypertension (2014) (0)
- Relationship between right ventricle remodeling index and outcomes in patients with pulmonary arterial hypertension and pre-tricuspid shunts (2021) (0)
- [Pulmonary arterial hypertension]. (2008) (0)
- A Meta-analysis: Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication (2023) (0)
- ELEVATE 2: Baseline Demographic Characteristics From the Phase IIB Study of the Efficacy and Safety of Two Doses of Rodatristat Ethyl When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (2023) (0)
- Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2) (2020) (0)
- Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study (2020) (0)
- Clinical and haemodynamic predictors of abnormal pulmonary vascular response at exercise (2015) (0)
- Clinical Characteristics And Survival Of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension Diagnosed By A Systematic Detection Program (2011) (0)
- Prolonged haloperidol induced Parkinsonism in a patient with cirrhosis (2008) (0)
- S122 Long-term survival and safety with selexipag in patients with pulmonary arterial hypertension: results from the GRIPHON study and its open-label extension (2018) (0)
- 0295: Characteristics of pulmonary hypertension in heart failure with preserved ejection fraction or pre capillary pulmonary hypertension (2016) (0)
- Screening pulmonary hypertension by lung doppler signal: A proof-of-concept study (2015) (0)
- Erythrocytes are altered in pulmonary arterial hypertension (2022) (0)
- breathlessness during exercise with advancing age Sex differences in the perceived intensity of (2015) (0)
- Pulmonary Arterial Hypertension: Conventional Therapy (2009) (0)
- type on clinical phenotypes of pulmonary arterial hypertension. (2012) (0)
- From Endothelin to Endothelin Receptor Antagonism: An Innovative Approach to Pulmonary Arterial Hypertension (2003) (0)
- What influences echocardiography reliability in estimation of pulmonary pressure? (2019) (0)
- [Treatment of porto pulmonary hypertension]. (2004) (0)
- [Surgical treatment of post-embolism pulmonary hypertension]. (2004) (0)
- Functional respiratory complaints among COVID-19 survivors: a prospective cohort study (2023) (0)
- Illicit drug use and pulmonary arterial hypertension: Not so frequent (2016) (0)
- 4.45 Prediction of operative mortality of pulmonary thrombo-endarterectomy in patients with chronic post-embolic pulmonary hypertension: value of right-ventricular function and hemodynamic parameters (2001) (0)
- Long-term outcome after percutaneous shunt closure of selected patients with atrial septal defect and severe pulmonary hypertension (2019) (0)
- Using controlled and real-world data in concert to assess survival in pulmonary arterial hypertension: Insights from SERAPHIN and REVEAL (2018) (0)
- Contents Vol. 85, 2013 (2013) (0)
- Pulmonary arterial hypertension in Adult-Onset Still’s Disease (2021) (0)
- Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension (2016) (0)
- Evaluation of a collaborative care program for pulmonary hypertension patients: a multicenter randomized trial (2020) (0)
- Complications pulmonaires de l'hypertension portale (2014) (0)
- [Pulmonary arterial hypertension]. (2005) (0)
- 0386: Prevalence, characteristics and prognosis of moderate to severe tricuspid regurgitation in patients with precapillary pulmonary hypertension (2016) (0)
- Do Parameters of Cardiac Function Predict Long-term Outcomes in Patients With Pulmonary Arterial Hypertension? Data From SERAPHIN, a Randomized Controlled Study of Macitentan (2013) (0)
- The Influence of Methods for Cardiac Output Determination on the Diagnosis of Precapillary Pulmonary Hypertension: A Mathematical Model (2023) (0)
- [Surgical treatment of chronic thromboembolic pulmonary hypertension]. (2014) (0)
- Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension: A randomised controlled trial (SERAPHIN) (2013) (0)
- Characteristics of PAH associated with pretricuspid shunts in the French PAH registry (2011) (0)
- From the authors: (2011) (0)
- Risk Stratification in Patients with Pulmonary Arterial Hypertension and Candidates for Lung or Heart-Lung Transplantation (2022) (0)
- Prevalence of hyperventilation syndrome in pulmonary arterial hypertension (2020) (0)
- Cardiac output by direct Fick, thermodilution and modelflow in pre-capillary pulmonary hypertension (2014) (0)
- Pulmonary veno-occlusive disease (PVOD) induced by chemotherapy: Experience from the French PH network and literature review (2013) (0)
- [Chronic post-embolic pulmonary artery hypertension]. (2007) (0)
- To be or not to be… treated with initial combination therapy, that is the (PAH) question (2022) (0)
- Lung capillary blood volume and membrane diffusion in PH (2014) (0)
- Erratum for Novel composite clinical endpoints and risk scores used in clinical trials in pulmonary arterial hypertension (2020) (0)
- PCV82 Characteristics and Outcomes of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Treated with Riociguat: A Retrospective, Observational Cohort Study (2020) (0)
- Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial (2023) (0)
- The total cross-sectional area of bronchial arteries predicts the extent of persistent PH after endarterectomy (2019) (0)
- Inclusion of echocardiographic measure of right ventricular function in the non-invasive French pulmonary arterial hypertension risk stratification method (2021) (0)
- 335 Characteristics of PAH associated with pretricuspid shunts in the registry of the French PAH network (2012) (0)
- Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN (2013) (0)
- Pulmonary thromboendarterectomy (PTE) in chronic thromboembolic pulmonary hypertension (CTE-PH): Impact on LV and RV function (1999) (0)
- Pulmonary arterial hypertension associated with fenfluramine exposure : report of 109 cases. Commentary (2008) (0)
- Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON (2020) (0)
- Devenir des patients candidats à une transplantation hépatique et atteints d’hypertension porto pulmonaire (2013) (0)
- Outcomes of patients with precapillary pulmonary hypertension admitted to an intensive care unit for acute right heart failure (2017) (0)
- 5022Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease (2017) (0)
- P17 Pharmacokinetics of macitentan in patients with portopulmonary hypertension: findings from the PORTICO sub-study (2018) (0)
- Risk stratification in pulmonary veno-occlusive disease (2022) (0)
- Recent Advances in Pulmonary Hypertension (2014) (0)
- Associations Between Serum Activin A and Follistatine-Like 3 Levels and Outcomes in Pulmonary Arterial Hypertension (2023) (0)
- [Hepatopulmonary syndrome: Prevalence, pathophysiology and clinical implications]. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Olivier Sitbon?
Olivier Sitbon is affiliated with the following schools:
